Best Healthcare Stocks to Buy in 2026

Healthcare Stocks at a Glance 2026

Why healthcare? The investment case

Healthcare is the one sector where demand is structurally non-discretionary. People need medicine and medical care regardless of recession, rate cycles, or consumer confidence. This makes healthcare one of the most defensive sectors — with a sector beta around 0.6, it falls roughly 40% less than the S&P 500 in market selloffs.

Beyond defensiveness, 2026 healthcare has genuine growth catalysts: 10,000 baby boomers turn 65 every day through 2030, driving peak Medicare enrollment. GLP-1 drugs are transforming obesity treatment — a $50B+ market growing to $150B+ by 2030. AI drug discovery is compressing 15-year development timelines. US healthcare at 17% of GDP is the world's largest healthcare market and growing.

Healthcare sub-sectors — know where you're investing

GLP-1 deep dive — the $150B+ drug opportunity

What are GLP-1 drugs? Glucagon-like peptide-1 receptor agonists were originally developed for Type 2 diabetes. The discovery that they cause 15–25% mean body weight reduction transformed them into the fastest-growing drug category in pharmaceutical history.

Who else competes? Amgen (MariTide — monthly injection, Phase 3), Pfizer (danuglipron — abandoned daily oral, pivoting to once-weekly), Viking Therapeutics (VK2735 — early data impressive), Rybelsus (NVO oral semaglutide — already approved, lower efficacy than injectable). Compounding pharmacies controversy: The FDA's shortage designation for semaglutide allowed compounding pharmacies to make cheaper versions. As supply constraints ease, the FDA is removing this designation — protecting NVO/LLY's branded pricing power.

Top healthcare stocks — full metrics table

AI scores use BriMindInvest's composite signal (20–96 scale). Operating margin shown for most recent reported fiscal year. Data June 2026.

UnitedHealth (UNH) — the healthcare sector's most misunderstood compounder

UnitedHealth is the largest US company by revenue at $350B+, yet trades at ~20x forward earnings — a discount to the S&P 500 average despite being one of the most durable compounders in the index. The company operates two interlocking businesses: UnitedHealthcare (health insurance, 50M+ members) and Optum (pharmacy benefits management, data analytics, and care delivery).

The Optum flywheel: Optum Health (care delivery — employs 90,000+ physicians) generates data that feeds Optum Insight (analytics sold to insurers and hospitals) which improves underwriting for UnitedHealthcare which attracts more members which generates more care data. Each component improves the others — a rare healthcare platform business with genuine network effects.

Regulatory risk: UNH faced significant scrutiny over prior authorization practices in 2024–2025. CMS mandated faster prior auth decisions (72-hour urgent, 7-day standard). While disruptive short-term, UNH's Optum data capabilities likely make it better-positioned than smaller competitors to comply efficiently. Medical Loss Ratio (MLR) rising in 2025 is the key near-term risk — any sustained MLR above 85% compresses margins meaningfully.

Margin comparison — gross margin vs operating margin

Gross margin above 60% is exceptional in pharma and med-tech — NVO (83%) and VRTX (88%) lead, reflecting premium branded drug pricing power. VRTX's cystic fibrosis monopoly (Trikafta) generates the highest gross margin in our universe. The gap between gross margin and operating margin shows R&D and SG&A investment: LLY invests aggressively (35% op. margin vs. 80% gross) to sustain its GLP-1 pipeline lead.

Drug patent cliffs — the pharma investor's biggest risk

Patent cliffs occur when a blockbuster drug loses exclusivity and generic/biosimilar competitors enter, often causing 50–90% price declines within 2 years. How companies manage patent cliffs separates great pharma investments from value traps.

AI in drug discovery — the 10-year structural tailwind

Traditional drug development takes 10–15 years from target identification to approval at a cost of $2–3B per approved drug (factoring in failures). AI is compressing this timeline at multiple stages: protein structure prediction (AlphaFold), virtual compound screening (10M+ compounds in days vs. years), clinical trial design optimization, and patient cohort matching.

• Alphabet / Isomorphic Labs: spinout of DeepMind's drug discovery unit; AlphaFold 3 predicting protein-molecule interactions at unprecedented accuracy; partnered with Novartis ($2.9B) and Eli Lilly ($1.7B)
• Recursion Pharmaceuticals (RXRX): biology-trained foundation models; acquired Exscientia (AI drug design); partnerships with Roche/Genentech
• AbSci: generative AI for antibody design; FDA cleared first AI-designed drug for clinical trial submission
• Big Pharma M&A: NVDA investing in AI drug discovery startups; every major pharma accelerating internal AI R&D capabilities

Investment implication: Pure-play AI drug discovery companies (RXRX, ABSI) are too early-stage for most investors — binary risk with 5–10 year timelines. The better play is owning large pharma companies actively deploying AI: LLY, NVO, MRK have the cash flow to fund internal AI programs and acquire AI tools at scale.

Healthcare ETFs — passive exposure options

XLV and VHT are the most cost-efficient choices for broad healthcare exposure. IBB captures large-cap biotech with less binary risk than small biotech. XBI's equal-weight approach gives small biotech meaningful allocation — highest risk/reward of the group, appropriate only as a satellite position.

Eli Lilly (LLY) — AI Score 88 · The GLP-1 category king

Eli Lilly's tirzepatide franchise (Mounjaro for Type 2 diabetes, Zepbound for obesity) is the fastest-growing drug in pharma history. In Q1 2026, combined tirzepatide revenue exceeded $5B for a single quarter — an annualised $20B+ run rate from a drug approved just three years ago.

Pipeline optionality: Orforglipron (oral small-molecule GLP-1) eliminates the injection barrier that limits GLP-1 adoption. Phase 3 data showing 15.6% weight reduction at 36 weeks — superior to semaglutide — validates the oral route. An oral obesity drug addresses a market 3–5x larger than injectable GLP-1 (most obese people will not self-inject). Donanemab (Alzheimer's) adds a second potential $10B+ franchise.

Manufacturing as the key constraint: Lilly has committed $23B to manufacturing capacity expansion through 2028 — two new US facilities specifically for GLP-1 fill-finish operations. Until capacity scales, demand exceeds supply in several markets. This is a high-class problem, but it explains why sequential revenue growth has been supply-constrained rather than demand-constrained.

ISRG · NVO · ABBV · ABT · UNH · MRK · VRTX

ISRG: Near-monopoly in soft-tissue robotic surgery with da Vinci 5 now shipping with AI surgical guidance. Razor-and-blades model generates $4B+/year in instruments/accessories — the recurring revenue stream that makes the 55x forward P/E more defensible than it looks. Read the full Intuitive Surgical report →

NVO: Cheapest forward P/E (28x) of the major GLP-1 players. CagriSema at 25mg dose showed 22.7% weight reduction — re-rating from the initial Phase 2 disappointment. The oral semaglutide programme is a potential $15B+ product. Trades at a significant discount to LLY despite comparable gross margins. Read the full Novo Nordisk report →

ABBV: Best value in large-cap pharma at 15x forward earnings. Skyrizi+Rinvoq passing Humira peak revenue is the key catalyst that has already partially played out — but is not fully reflected in the multiple. 4th Skyrizi indication (UC) approved in 2026. Dividend yield of ~3.5% provides income while you wait for multiple re-rating.

VRTX: Cystic fibrosis monopoly (Trikafta) with 88% gross margin — highest in pharmaceutical industry. Pain pipeline (suzetrigine) is the next potential blockbuster; non-opioid pain treatment addressing a massive market. Fortress balance sheet with $10B+ cash.

MRK: Cheapest large pharma at 11x forward earnings. Keytruda (pembrolizumab) is the world's best-selling cancer drug with 40+ approved indications. Patent cliff in 2028 is the key risk — manageable if MRK's pipeline (Winrevair pulmonary hypertension, subcutaneous Keytruda) delivers.

Recent news and catalysts

Q2 2026 earnings season (reported July–August 2026) is now complete for all eight names in this list. Here's what actually moved, verified against company filings and earnings releases:

Forward P/E, analyst buy/sell counts, and price targets in the tables above reflect the original June 2026 data and were not re-verified for this update — those figures move too quickly for a periodic content refresh to keep current with confidence.

Bottom line verdict

For 2026, the strongest healthcare investments are: NVO (best value among GLP-1 plays at 28x; underappreciated pipeline), ABBV (best value in large-cap pharma at 15x with proven patent cliff navigation), and UNH (cheap compounder at 20x with Optum platform advantages).

For GLP-1 pure conviction, LLY remains the highest-conviction pick despite the 48x multiple — the orforglipron oral GLP-1 could 3–5× the addressable market if Phase 3 succeeds. For passive healthcare exposure with low cost, XLV at 0.09% ER is the default choice.

Frequently asked questions

Compare healthcare stocks

Free AI scores, pipeline data, operating margins, and analyst targets for any two healthcare stocks.

Read Next